@article{MTMT:34766579,
	title = {Exploratory study of blood biomarkers in patients with post-stroke epilepsy},
	url = {https://m2.mtmt.hu/api/publication/34766579},
	author = {Abraira, Laura and López-Maza, Samuel and Quintana, Manuel and Fonseca, Elena and Toledo, Manuel and Campos-Fernández, Daniel and Lallana, Sofía and Grau-López, Laia and Ciurans, Jordi and Jiménez, Marta and Becerra, Juan Luis and Bustamante, Alejandro and Rubiera, Marta and Penalba, Anna and Montaner, Joan and Álvarez Sabin, José and Santamarina, Estevo},
	doi = {10.1177/23969873241244584},
	journal-iso = {EU STROKE J},
	journal = {EUROPEAN STROKE JOURNAL},
	unique-id = {34766579},
	issn = {2396-9873},
	year = {2024},
	eissn = {2396-9881},
	orcid-numbers = {Abraira, Laura/0000-0002-5119-7929; Lallana, Sofía/0000-0002-5999-9889; Rubiera, Marta/0000-0001-8100-9477}
}

@article{MTMT:34569393,
	title = {Subarachnoidalis vérzés intenzív osztályos kezelése: úton a személyre szabott medicina felé},
	url = {https://m2.mtmt.hu/api/publication/34569393},
	author = {Molnár, Tihamér},
	journal-iso = {FOCUS MEDICINAE},
	journal = {FOCUS MEDICINAE},
	volume = {25},
	unique-id = {34569393},
	issn = {1419-0478},
	year = {2024},
	pages = {15-18}
}

@article{MTMT:34480100,
	title = {Biomarkers in aneurysmal subarachnoid hemorrhage: A short review},
	url = {https://m2.mtmt.hu/api/publication/34480100},
	author = {Batista, S. and Bocanegra-Becerra, J.E. and Claassen, B. and Rubião, F. and Rabelo, N.N. and Figueiredo, E.G. and Oberman, D.Z.},
	doi = {10.1016/j.wnsx.2023.100205},
	journal = {World neurosurgery: X},
	volume = {19},
	unique-id = {34480100},
	issn = {2590-1397},
	year = {2023}
}

@article{MTMT:33638416,
	title = {Elevated Levels of the Cytokine LIGHT in Pediatric Crohn’s Disease},
	url = {https://m2.mtmt.hu/api/publication/33638416},
	author = {Cardinale, Christopher J. and Abrams, Debra J. and Mentch, Frank D. and Cardinale, John A. and Wang, Xiang and Kao, Charlly and Sleiman, Patrick M. A. and Hakonarson, Hakon},
	doi = {10.4049/jimmunol.2200652},
	journal-iso = {J IMMUNOL},
	journal = {JOURNAL OF IMMUNOLOGY},
	volume = {210},
	unique-id = {33638416},
	issn = {0022-1767},
	abstract = {LIGHT (homologous to lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for herpes virus entry mediator, a receptor expressed by T lymphocytes), encoded by the TNFSF14 gene, is a cytokine belonging to the TNF superfamily. On binding to its receptors, herpes virus entry mediator and lymphotoxin β receptor, it activates inflammatory responses. We conducted this study to determine whether plasma LIGHT levels are elevated in Crohn’s disease (CD) in a pediatric population with the aim of nominating this cytokine as a therapeutic target. We used a single-molecule immunoassay to determine the circulating levels of free LIGHT in plasma from pediatric patients with CD in our biobank (n = 183), a panel of healthy pediatric (n = 9) or adult (n = 22) reference samples, and pediatric biobank controls (n = 19). We performed correlational analyses between LIGHT levels and the clinical characteristics of the CD cohort, including age, Montreal classification, family history, medical/surgical therapy, and routine blood test parameters. LIGHT levels were greatly elevated in CD, with an average of 305 versus 32.4 pg/ml for controls from the biobank (p < 0.0001). The outside reference samples showed levels of 57 pg/ml in pediatric controls and 55 pg/ml in adults (p < 0.0001). We found a statistically significant correlation between white blood cell count and free LIGHT (p < 0.046). We conclude that free, soluble LIGHT is increased 5- to 10-fold in pediatric CD across an array of disease subtypes and characteristics.},
	year = {2023},
	eissn = {1550-6606},
	pages = {590-594},
	orcid-numbers = {Cardinale, Christopher J./0000-0001-7513-8977; Mentch, Frank D./0000-0003-4889-6961; Hakonarson, Hakon/0000-0003-2814-7461}
}

@article{MTMT:34206076,
	title = {Potential application of peripheral blood biomarkers in intracranial aneurysms},
	url = {https://m2.mtmt.hu/api/publication/34206076},
	author = {Wu, Yangying and Zhao, Ziya and Kang, Shaolei and Zhang, Lijuan and Lv, Fajin},
	doi = {10.3389/fneur.2023.1273341},
	journal-iso = {FRONT NEUR},
	journal = {FRONTIERS IN NEUROLOGY},
	volume = {14},
	unique-id = {34206076},
	issn = {1664-2295},
	year = {2023},
	eissn = {1664-2295}
}

@article{MTMT:33050416,
	title = {Serum Periostin May Help to Identify Patients with Poor Collaterals in the Hyperacute Phase of Ischemic Stroke},
	url = {https://m2.mtmt.hu/api/publication/33050416},
	author = {Spántler, Dóra and Csécsei, Péter and Böröcz, Katalin and Berki, Tímea and Zavori, Laszlo and Schwarcz, Attila and Lenzsér, Gábor and Molnár, Tihamér},
	doi = {10.3390/diagnostics12081942},
	journal-iso = {DIAGNOSTICS},
	journal = {DIAGNOSTICS},
	volume = {12},
	unique-id = {33050416},
	issn = {2075-4418},
	abstract = {Background: Periostin is a glycoprotein that mediates cell functions in the extracellular matrix and appears to be a promising biomarker in neurological damage, such as ischemic stroke (IS). We aimed to measure serum periostin levels in the hyperacute phase of ischemic stroke to explore its predictive power in identification of patients with poor collaterals (ASPECT < 6). Methods: We prospectively enrolled 122 patients with acute ischemic stroke within the first 6 h after onset. The early ischemic changes were evaluated by calculating ASPECT score on admission using a native CT scan. An unfavorable outcome was defined as the modified Rankin Scale (mRS) > 2 at 90 days follow-up. Blood samples were collected on admission immediately after CT scan and periostin serum concentrations were determined by ELISA. Results: The admission concentration of serum periostin was significantly higher in patients with unfavorable outcome than in patients with favorable outcome (615 ng/L, IQR: 443–1070 vs. 390 ng/L, 260–563, p < 0.001). In a binary logistic regression model, serum periostin level was a significant predictor for ASPECT < 6 status on admission, within 6 h after stroke onset (OR, 5.911; CI, 0.990–0.999; p = 0.015). Conclusion: Admission periostin levels can help to identify patients who are not suitable for neurointervention, especially if advanced neuroimaging is not available.},
	year = {2022},
	eissn = {2075-4418},
	orcid-numbers = {Berki, Tímea/0000-0002-0134-8127; Zavori, Laszlo/0000-0002-1715-4167; Molnár, Tihamér/0000-0002-6149-9787}
}

@article{MTMT:31963966,
	title = {Neurointenzív Tanszék – az első év},
	url = {https://m2.mtmt.hu/api/publication/31963966},
	author = {Molnár, Tihamér and Ezer, Erzsébet},
	journal-iso = {FOCUS MEDICINAE},
	journal = {FOCUS MEDICINAE},
	volume = {23},
	unique-id = {31963966},
	issn = {1419-0478},
	year = {2021},
	pages = {3-5}
}

@article{MTMT:32165067,
	title = {Fatty Acid-Binding Protein 3 and CXC-Chemokine Ligand 16 are Associated with Unfavorable Outcome in Aneurysmal Subarachnoid Hemorrhage},
	url = {https://m2.mtmt.hu/api/publication/32165067},
	author = {Schranz, Dániel and Molnár, Tihamér and Erdő-Bonyár, Szabina and Simon, Diána and Berki, Tímea and Závori, László and Szolics, Alex and Büki, András and Lenzsér, Gábor and Csécsei, Péter},
	doi = {10.1016/j.jstrokecerebrovasdis.2021.106068},
	journal-iso = {J STROKE CEREBROVASC DIS},
	journal = {JOURNAL OF STROKE AND CEREBROVASCULAR DISEASES},
	volume = {30},
	unique-id = {32165067},
	issn = {1052-3057},
	abstract = {Aneurysmal subarachnoid hemorrhage (aSAH) is associated with activation of the inflammatory cascade contributing to unfavorable outcome and secondary complications, such as delayed cerebral ischemia (DCI). Both fatty acid-binding protein 3 (FABP3) and CXC-chemokine ligand 16 (CXCL-16) have been linked to vascular inflammation and cellular death. The authors aimed to assess the 30-day prognostic value of serum levels of FABP3 and CXCL-16 and explore their associations with DCI in aSAH patients.A total of 60 patients with aSAH were prospectively enrolled. Sampling for markers was done at 24 hours after the index event. FABP3 and CXCL-16 serum concentrations were determined by MilliPlex multiplex immunoassay method. The primary endpoint was unfavorable outcome at Day 30 based on the modified Rankin Scale.Both FABP3 and CXCL-16 levels were significantly elevated in patients with unfavorable outcome compared to those with favorable outcome after aSAH (FABP3: 2133 pg/mL, IQR: 1053-4567 vs. 3773, 3295-13116; p<0.003 and CXCL-16: 384 pg/mL, 313-502 vs. 498, 456-62, p<0.001). The area under the curve (AUC) for serum CXCL-16 levels as a predictor of unfavorable outcome at Day 30 was 0.747 (95% CI =0.622-0.871; p<0.001). Based on binary logistic regression analysis, serum CXCL-16 with a cut-off level >446.7 ng/L independently predicted Day 30 unfavorable outcome with a sensitivity of 81% and a specificity of 62%. Neither CXCL-16 nor FABP3 showed a significant correlation with DCI.Early FABP3 and CXCL-16 levels are significantly associated with poor 30-day outcome in patients with aSAH.},
	keywords = {SUBARACHNOID HEMORRHAGE; FABP3; CXCL-16; Unfavorable outcome},
	year = {2021},
	eissn = {1532-8511},
	orcid-numbers = {Berki, Tímea/0000-0002-0134-8127; Závori, László/0000-0002-1715-4167}
}